file8kubs.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
________________
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of Earliest Event Reported) – June 2, 2009
 
________________________
 
WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)
 
_____________________

     
Pennsylvania
1-8036
23-1210010
(State or other jurisdiction
of incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
     
101 Gordon Drive, PO Box 645, Lionville, PA
  
19341-0645
(Address of principal executive offices)
  
(Zip Code)
 
610-594-3319
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name or address, if changed since last report)
____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 


 
Item 7.01   Regulation FD Disclosure
 
 
On May 29, 2009, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer, and William J. Federici, Chief Financial Officer, will make a presentation at the UBS 2009 Global Specialty Pharmaceuticals Conference at 9:00 am GMT on Wednesday, June 3, 2009 in London, England.
 
 
A copy of the Company’s presentation from the conference will be available for 30 days through the Investors link at the Company’s website, http://www.westpharma.com., and is also attached hereto as Exhibit 99.1.  A copy of the press release is attached hereto as Exhibit 99.2.  Both Exhibits are incorporated herein by reference.
 
 
The information in this report (including Exhibit 99.1 and 99.2) is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
 
 
Item 9.01   Financial Statements and Exhibits
 
(d)
Exhibits
    
       
 
Exhibit #
  
Description
 
99.1
  
West Pharmaceutical Services, Inc. Corporate Overview (Investor Presentation).
       
 
99.2
  
West Pharmaceutical Services, Inc. Press Release, dated May 29,  2009.

 

 
 

 

 
2
 

 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 

 
WEST PHARMACEUTICAL SERVICES, INC.
 
/s/ John R. Gailey III
John R. Gailey III
Vice President, General Counsel and Secretary
 

 
 
June 2, 2009
 
 

 

 
3